Research map: Letter in reply: should SNRIs be considered the most effective neuromodulators for IBS?

Back to the article

Papers in this map

  1. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial · Alexander Charles Ford · 2023 · 143 citations · Cited by this paper
  2. A patient-driven agenda for liver cirrhosis research · 2026 · Related
  3. Effect of Brain-Gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis · Vivek Chand Goodoory · 2024 · 57 citations · Cited by this paper
  4. International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials · 2026 · Related
  5. Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation · Tony Kendrick · 2023 · 32 citations · Cited by this paper
  6. Toward a CKLM framework for integrated clinical trial design · 2026 · Related
  7. Efficacy of gut–brain neuromodulators in irritable bowel syndrome: an updated systematic review and meta-analysis · Mais Khasawneh · 2025 · 26 citations · Cited by this paper
  8. Large language models for detecting colorectal polyps in endoscopic images—further research is required · 2026 · Related
  9. Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis · Elyse R. Thakur · 2025 · 22 citations · Cited by this paper
  10. USP20 promotes CD8 + T cell exhaustion and impairs KRAS G12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer · 2026 · Related
  11. Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial · Alexandra M. Wright-Hughes · 2025 · 14 citations · Cited by this paper
  12. Galectin-14, a primate-specific oncofetal protein, impairs anti-tumour immunity in hepatocellular carcinoma by driving elevated heparan sulphate modification · 2026 · Related
  13. Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis · Mais Khasawneh · 2026 · 3 citations · Cited by this paper
  14. Cancer neuroscience in cholangiocarcinoma: from perineural invasion to neuroimmune control · 2026 · Related
  15. Should serotonin-noradrenaline reuptake inhibitors be considered the most effective neuromodulators for irritable bowel syndrome? · Christian von Mühlenbrock · 2026 · 1 citation · Cited by this paper
  16. Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality · 2026 · Related
  17. Safety and efficacy of extended surveillance intervals following colorectal endoscopic submucosal dissection: an international multicentre study · 2026 · Related

Source: OpenAlex (CC0)